prolactinoma/umor

Veza se sprema u međuspremnik

ČlanciKliničkim ispitivanjimaPatenti

Odaberite vrstu sortiranja

9 rezultati

[Results of treatment for male prolactinomas].

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

We evaluated the results of medical treatment for male prolactinomas. We encountered eight patients with male prolactinomas. The age was 25 to 54 years old (mean 43 years) and the chief clinical symptoms were visual acuity/field defect in three patients, pituitary apoplexy in one patient,

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.A 27-year-old

Autonomic failure mimicing dopamine agonist induced vertigo in a patient with macroprolactinoma.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

A 68-year-old man presented with general fatigue, increasing adynamia, weakness, vertigo and recurrent syncope. Six weeks earlier the diagnosis of a macroprolactinoma had been established based on a greatly elevated prolactin concentration (161 170 micro U/l) and MR-evidence of a 3.5 cm measuring

The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Prolactinomas are common pituitary tumors that can cause gonadal dysfunction and infertility related to hyperprolactinemia. Dopamine agonists are the first-line treatment in these patients. Cabergoline leads to significant reduction in serum prolactin levels and tumor size in patients with

An unusual collision tumor comprising a prolactinoma and a plasmocytoma originating from the sellar region.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

A 58-year-old previously healthy man presented with diplopia of rapid onset over a few days. Examination demonstrated bilateral sixth and right fourth cranial nerve palsy. MR imaging showed a large sellar mass with significant destruction of the pituitary fossa. Laboratory tests revealed very high

Quality of life is decreased in female patients treated for microprolactinoma.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

OBJECTIVE Most studies on treatment of microprolactinoma have focused on clinical and biochemical outcome rather than on functional and mental well-being. We evaluated this topic in female patients with microprolactinoma, because other pituitary adenomas are associated with decreased quality of

The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

OBJECTIVE We assessed the efficacy and safety of the new, long-acting dopamine agonist drug cabergoline during long-term therapy of hyperprolactinaemia. METHODS Open, prospective, multicentre study. METHODS One hundred and sixty-two females with either a microprolactinoma (n = 100), idiopathic

Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

OBJECTIVE Dopamine agonists have a well established place in the treatment of hyperprolactinaemic disorders but their use is associated with a high incidence of adverse effects. We have investigated the biochemical efficacy and side-effect profile of a range of doses of the novel, long-acting

Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

OBJECTIVE Quality of life (QoL) is impaired in patients treated for pituitary adenomas. However, differences in age and gender distributions hamper a proper comparison of QoL. Therefore, we compared age- and gender-specific standard deviations (SD) scores (Z-scores) of QoL parameters in patients

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta naukom

Radi na 55 jezika
Biljni lijekovi potpomognuti naukom
Prepoznavanje biljaka po slici
Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
Pročitajte naučne publikacije povezane sa vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima